Jae-Hoon Kang,Hong-Sub Lee,Kyung-Mi An,Chang-Hee Hong,Hyun-Jung Kwak,Shuo-Lin Cui,Hyo-Jung Song
申请号：
US16467654
公开号：
US20200223833A1
申请日:
2017.12.14
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to the compounds according to Formula (1), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (1) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.
